The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson's disease

Movement Disorders

Volumn 14, Issue 6, 1999, Pages 940-946

  Ahlskog, J Eric ^a   Uitti, Ryan J ^b   O'Connor, Michael K ^a   Maraganore, Demetrius M ^a   Matsumoto, Joseph Y ^a   Stark, Kathy F ^a   Turk, Margaret F ^b   Burnett, Omer L ^b  

^a MAYO CLINIC   (United States)

^b NONE

Author keywords

123I CIT; Dopamine agonist; Dopamine transporter; Parkinson's disease; Pergolide; SPECT

Indexed keywords

3BETA (4 IODOPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; AMANTADINE; CARBIDOPA PLUS LEVODOPA; DOPAMINE RECEPTOR STIMULATING AGENT; DOPAMINE TRANSPORTER; IODINE 123; LEVODOPA; PERGOLIDE; SELEGILINE;

ADULT; AGED; ARTICLE; CAUDATE NUCLEUS; CLINICAL ARTICLE; CORPUS STRIATUM; DISEASE COURSE; DRUG UPTAKE; HUMAN; OCCIPITAL CORTEX; ORAL DRUG ADMINISTRATION; PARKINSON DISEASE; PRIORITY JOURNAL; PUTAMEN; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

AGED; BRAIN; BRAIN MAPPING; CARBIDOPA; CARRIER PROTEINS; COCAINE; CORPUS STRIATUM; DOPAMINE AGONISTS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IODINE RADIOISOTOPES; LEVODOPA; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; MOTOR SKILLS; NERVE TISSUE PROTEINS; PARKINSON DISEASE; PERGOLIDE; PUTAMEN; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0032721931     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/1531-8257(199911)14:6<940::AID-MDS1005>3.0.CO;2-Y     Document Type: Article

References (25)

1. Uhl GR. Neurotransmitter transporter (plus): a promising new gene family. Trends Neurosci 1992;15:265-268.
2. Innis RB, Seibyl JP, Scanlry BE, et al. Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson's disease. Proc Natl Acad Sci USA 1993;90:11965-11969.
3. 123I]beta-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol 1995;38:589-598.
4. 123I] beta-CIT binding with SPECT in controls, early and late Parkinson's disease. Nucl Med Biol 1995;22:985-991.
5. 123I] beta-CIT/SPECT imaging demonstrated bilateral loss of dopamine transporters in hemi-Parkinson's disease. Neurology 1996;46:231-237.
6. Asenbaum S, Brucke T, Pirker W, et al. Imaging of dopamine transporters with iodine-123-beta-CIT and SPECT in Parkinson's disease. J Nucl Med 1997:38:1-6.
7. 123I]beta-CIT. Mov Disord 1999;14:436-442.
8. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N Engl J Med 1988;318:876-880.
9. Brooks DJ, Ibanez V, Sawle GV, et al. Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol 1990;28:547-555.
10. Koller WC, ed. Handbook of Parkinson's Disease. New York, NY: Marcel Dekker, 1987.
11. 123I]beta-CIT: pharmacological characterization of brain uptake in nonhuman primates. Synapse 1993;13:295-309.
12. Thibaut F, Bonnet JJ, Vaugeois JM, Costentin J. Pharmacological modifications of dopamine transmission do not influence the striatal in vivo binding of [3H]mazindol or [3H]cocaine in mice. Neurosci Lett 1996;205:145-148.
13. Dresel SH, Kung MP, Plossl K, Meegalla SK, Kung HF. Pharmacological effects of dopaminergic drugs on in vivo binding of [99mTc]TRODAT-1 to the central dopamine transporters in rats. Eur J Nucl Med 1998;25:31-39.
14. Little KY, Gorebig J, Carroll FI, Mapili J, Meador-Woodruff JH. Lack of dopamine receptor agonists effect on striatal dopamine tranporter binding sites. Brain Res 1996;742:313-316.
15. Gordon I, Weizman R, Rehavi M. Modulatory effect of agents active in the presynaptic dopaminergic system on the striatal dopamine transporter. Eur J Pharmacol 1996;298:27-30.
16. Moody CA, Granneman JG, Bannon MJ. Dopamine transporter binding in rat striatum and nucleus accumbens is unaltered following chronic changes in dopamine levels. Neurosci Lett 1996;217: 55-57.
17. Ikawa K, Watanabe A, Kaneno S, Toru M. Modulation of [3H]mazindol binding sites in rat striatum by dopaminergic agents. Eur J Pharmacol 1993;250:261-266.
18. Gnanalingham KK, Robertson RG. The effects of chronic continuous versus intermittent levodopa treatments on striatal and extrastriatal D1 and D2 dopamine receptors and dopamine uptake sites in the 6-hydroxydopamine lesioned rat - an autoradiographic study. Brain Res 1994;640:185-194.
19. Perachon S, Schwartz J-C, Sokoloff P. Binding and functional potencies of bromocriptine, pramipexole, pergolide and ropinirole at D1, D2 and D3 receptors [Abstract]. Neurology 1998;50(suppl 4):A134.
20. Piercey MF, Hoffman WE, Smith MW, Hyslop DK. Inhibition of dopamine meuron firing by pramipexole, a dopamine D3 receptor-preferring agonist: comparison to other dopamine receptor agonists. Eur J Pharmacol 1996;312:35-44.
21. Tulloch IF. Pharmacologic profile of ropinirole: a nonergoline dopamine agonist. Neurology 1997;49(suppl 1):S58-S62.
22. Ichise M, Ballinger JR, Tanaka F, et al. Age-related changes in D2 receptor binding with iodine-123-iodobenzofuran SPECT. J Nucl Med 1998;39:1511-1518.
23. Leong LK, O'Connor MK, Maraganore DM. Quantitation of iodine-123-beta-CIT dopamine receptor uptake in a phantom model. J Nucl Med Technol 1999;27:117-122.
24. Seibyl JP, Laruelle M, van Dyck CH, et al. Reproducibility of iodine-123-beta-CIT SPECT brain measurement of dopamine transporters. J Nucl Med 1996;37:222-228.
25. Seibel JP, Marek KL, Sheff K, et al. Test/retest reproducibility of iodine-123betaCIT SPECT brain measurement of dopamine transporters in Parkinson's patients. J Nucl Med 1997;38:1453-1459.